Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958997 · ClinicalTrials.gov registry record
Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 16
- Enrollment target
NCT00958997 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 16 participants.
The verdict
NCT00958997 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Pancreatic Islet beta-cells are responsible for synthesizing and secreting appropriate amounts of insulin to regulate blood glucose levels. One factor in the development of diabetes is the loss of beta-cells. Developing treatments to prevent or restore islet beta-cell mass (BCM) in diabetic patients is hampered by a lack of methods for the non-invasive imaging of these cells. This study is designed to evaluate a radiolabeled compound that binds to the pancreatic islet. The investigators will test the ability of one promising imaging compound, 18F-9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ), to measure the amount of pancreatic islet beta-cells in patients with long-standing type-1 diabetes and in age-weight-matched healthy control subjects.
Interventions
- DRUG 18F-FP-DTBZ (18F-AV-133)
- BIOLOGICAL Arginine-hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958997
The ClinicalTrials.gov registry entry for NCT00958997 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-FP-DTBZ (18F-AV-133) is the first listed.
NCT00958997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958997 about?
NCT00958997 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients". Pancreatic Islet beta-cells are responsible for synthesizing and secreting appropriate amounts of insulin to regulate blood glucose levels. One factor in the development of diabetes is the loss of beta-cells. Developing treatments to prevent or restore islet beta-cell mass (BCM) in diabetic patients...
What is the current status of trial NCT00958997?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2009-08. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00958997?
The interventions under investigation include: 18F-FP-DTBZ (18F-AV-133) (DRUG), Arginine-hydrochloride (BIOLOGICAL).
Who is sponsoring clinical trial NCT00958997?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.